OncoTribune Contents

OncoTribune コンテンツ紹介

学会速報レポート

Congress Report

海外学会などで発表されたホットでタイムリーな演題を専門医が厳選。レポートとコメントを掲載します。

臨床試験サマリ

Executive Summary of Cancer Clinical Trials

各領域で発表されている臨床試験を分かりやすくサマライズして掲載します。

座談会

Round Table Discussion

各領域のエキスパートによるディスカッションした内容を掲載します

Latest Updates

新着コンテンツ

ASCO-GI 2020 FLASH REPORT - Abstract 133 - 大腸癌 Oral

Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Eyal Meiri, MD

ASCO-GI 2020 FLASH REPORT - Abstract 638 - 肝胆膵癌 Oral

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma.
First Author: Margaret A. Tempero, MD, FASCO

ASCO-GI 2020 FLASH REPORT - Abstract 278 - 胃癌 Oral

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
First Author: Markus H. Moehler, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 1 - 大腸癌 Oral

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.
First Author: Aurelien Marabelle, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 476 - 肝胆膵癌 Oral

Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
First Author: Peter R. Galle, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 5 - 大腸癌 Oral

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
First Author: Yoshiaki Nakamura

ASCO-GI 2020 FLASH REPORT - Abstract 281 - 食道癌 Oral

A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study.
First Author: Maarten C.C.M. Hulshof, MD PhD

ASCO-GI 2020 FLASH REPORT - Abstract 100 - 大腸癌 Poster

VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.
First Author: Takeshi Kato, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 478 - 肝胆膵癌 Oral

Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau

ASCO-GI 2020 FLASH REPORT - Abstract 7 - 大腸癌 Oral

A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS).
First Author: Yukihide Kanemitsu, MD